Noviembre 2022
La compañía gallega Oncostellae abre una ampliación de capital de 3,3 millones de euros para desarrollar un fármaco para la colitis ulcerosa y un segundo para el cáncer colorrectal

noviembre 3, 2022

---

La biofarmacéutica especializada en moléculas para tratamientos de enfermedades gastrointestinales cuenta con dos proyectos muy avanzados, un primero en fase clínica…

Read More

February 2020
Oncostellae received regulatory approval to start a proof of concept study with OST-122 in patients with ulcerative colitis

febrero 21, 2020

---

Oncostellae has received permission from the regulator to start a Phase 2a study with OST-122 in patients suffering from ulcerative colitis….

Read More

11 October 2019
IO4COLON project progress

febrero 21, 2020

---

Investigación industrial para el descubrimiento de nuevos fármacos inmunoterapéuticos en tratamiento de cáncer de colon. El pasado viernes (11 de octubre…

Read More

May 2019
OST-122 has successfully completed a Phase 1b trial in HV and has proved to be GI-restricted and well tolerated up to 1200 mg after multiple dosing

febrero 20, 2020

---

Following a successful randomized, double-blind, placebo-controlled Phase 1a clinical trial in healthy volunteers which was carried out at the Sant Pau…

Read More

10 Dec 2018
GI-restricted Jak3/Tyk2 inhibitor OST-122 well tolerated in clinical phase Ia study

marzo 24, 2019

---

OST-122, a novel, gut-restricted Jak3/Tyk2 inhibitor for the local treatment of gastrointestinal diseases, has completed the first part of a randomized,…

Read More

23 Jul 2018
Oncostellae initiated clinical development of OST-122

marzo 24, 2019

---

Oncostellae has started today a first-in-human study of OST-122, its novel, gut-restricted Jak3/Tyk2 inhibitor that is being developed for the local…

Read More

22 Feb 2019
IO4COLON Project Presentation

febrero 23, 2019

---

Last 22th of February at 12:00 pm was celebrated the Presentation of IO4COLON Project in the CIQUS Research Center We are pleased…

Read More

02 Jul 2018
Neogalfarm Project Results

julio 2, 2018

---

Nuevos fármacos contra el cáncer: Desarrollo de terapias dirigidas a diferentes dianas terapéuticas y de tratamientos combinados Período de ejecución: Febrero…

Read More